Rubella Virus IgG ELISA kit (avidity)
Be the first to review this product! Submit a review
|
(0 Publication)
- Colorimetric readout - 450 nm - Works on any standard plate reader
- Easy results interpretation
Reactivity data
Product details
Rubella Virus IgG ELISA kit (avidity) (ab247202) is designed to indicate the Rubella-specific IgG avidity in human serum or plasma (citrate, heparin) to differentiate between acute and past infection.
The qualitative immunoenzymatic determination of specific antibodies is based on the ELISA (Enzyme-linked Immunosorbent Assay) technique. Microplates are coated with specific antigens to bind corresponding antibodies of the sample (dual pipetting). After washing the wells to remove all unbound sample material, one well is incubated with avidity reagent and the corresponding well with washing buffer. The avidity reagent removes the low-avidity antibodies from the antigens whereas the high-avidity ones are still bound to the specific antigens. After a second washing step to remove the rest of avidity reagent and low-avidity antibodies, a horseradish peroxidase (HRP) labelled conjugate is added. This conjugate binds to the captured antibodies. In a third washing step unbound conjugate is removed. The immune complex formed by the bound conjugate is visualized by adding Tetramethylbenzidine (TMB) substrate which gives a blue reaction product. The intensity of this product is proportional to the amount of specific antibodies in the sample. Sulphuric acid is added to stop the reaction. This produces a yellow endpoint colour. Absorbance at 450/620 nm is read using an ELISA microwell plate reader.
The presence of IgG antibodies to Rubella Virus indicates the occurrence of the infection but does not distinguish between recent and past infection. Virus-specific IgM antibodies are first detected approximately in ten days and peak at about four weeks post infection. They may persist for several months after acute infections. Based on the evidence that antibody avidity gradually increases after exposure to an immunogen, avidity of IgG antibodies can be used as a marker for distinguishing recent primary from long-term infections. Avidity describes the binding strength of a specific antibody to its antigen. Low-avidity IgG antibodies indicate a primary infection, whereas the presence of IgG antibodies with high avidity points to persistency or reactivation of infection.
What's included?
Properties and storage information
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
Anti-rubella IgG antibodies play a significant role in neutralizing the rubella virus and preventing its replication. These antibodies do not act as part of a larger protein complex but instead bind directly to antigens on the virus surface. If the antibodies demonstrate high avidity they indicate a mature immune response which could be significant in determining the timing of rubella infection. A high avidity index often suggests past infection or vaccination providing valuable information about the rubella immunity status. Therefore measuring the avidity of anti-rubella IgG can help distinguish between recent and past infections.
Pathways
The immune response pathways involve these antibodies as a part of the adaptive immune response. Key pathways include the humoral immune response where B cells produce specific antibodies against rubella after recognizing the virus antigens. Other proteins such as CD4+ T-helper cells assist B cells in differentiating into plasma cells that secrete these antibodies. This process strengthens the body's defense mechanisms by equipping it with memory against future rubella exposures.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
- Download websiteProtocolBooklet|en
Target data
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com